Attention to Health Education, NIPT Grants and Genetic Counseling Boosts Industry

company logo

Non-Invasive Prenatal Testing Market

Non-Invasive Prenatal Testing Market

Non-Invasive Prenatal Testing Market

Dublin, Nov. 18, 2022 (GLOBE NEWSWIRE) — The “Noninvasive Prenatal Testing Market, By Test Type, By Application, By End-User, And By Region – Size, Share, Outlook, and Opportunity Analysis, 2022-2030” report has been added to from ResearchAndMarkets.com offer.

Non-Invasive Prenatal Testing (NIPT) is also known as Non-Invasive Prenatal Screening (NIPS). This is a procedure used to determine chromosomal abnormalities or disorders in the fetus that usually occur due to a missing or extra copy (aneuploidy) of a chromosome. NIPT examines the small fragments of deoxyribonucleic acid (DNA) that circulate in the pregnant woman’s blood. These small fragments are free-floating and are therefore called cell-free DNA. NIPT is performed for the detection of trisomy 18, trisomy 13, Down syndrome and missing or extra copies of X and Y chromosomes. NIPT is proving useful during the COVID-19 pandemic situation to prevent the risk of infection. The ability to isolate fetal DNA and fetal cells from maternal blood during pregnancy has revealed exciting opportunities for improving non-invasive prenatal testing (NIPT).

Market dynamics

Securing reimbursement for the tests from payers is expected to provide lucrative growth opportunities for players in the global non-invasive prenatal testing market. Vendors can focus on obtaining insurance coverage for the NIPT tests they offer, given the high costs of these tests. Additionally, the focus on health education, subsidies for NIPT, and genetic counseling are also expected to contribute to market growth.

For example, in September 2020, researchers from Fudan University, China, and University College London, UK, reported that in China, compared to participants in Zhengzhou, a higher proportion high percentage of women in Shenzhen had heard of NIPT (87.30% vs. 64.03%). , were willing to receive NIPT (91.80% versus 80.43%) and had taken NIPT (83.12% versus 54.54%), while their level of satisfaction was lower.

Main characteristics of the study:

  • This report provides an in-depth analysis of the global Non-Invasive Prenatal Testing market and provides the market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), by considering 2021 as the base year

  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.

  • This study also provides key insights into the market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.

  • It profiles leading players of the global Non-Invasive Prenatal Testing Market based on the following parameters: Company Highlights, Product Portfolio, Key Highlights, Financial Performance and Strategies

  • The information in this report would enable marketers and managing authorities of companies to make informed decisions regarding their future product launches, type upgrades, market expansion and marketing tactics.

  • The Global Non-Invasive Prenatal Testing Market report is targeted at various stakeholders of this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

  • Stakeholders would have an ease in making decisions through various strategic matrices used to analyze the global Non-Invasive Prenatal Testing market

Detailed segmentation:
Global non-invasive prenatal testing market, by type of test:

  • Panel 1 trial

  • Panel 2 test

  • Panel 3 trial

Global Non-Invasive Prenatal Testing Market, By Application:

Global Non-Invasive Prenatal Testing Market, By End User:

  • Hospitals

  • Diagnostic laboratories

  • Maternity centers

Global Non-Invasive Prenatal Testing Market, By Region:

  • North America

  • By country

  • WE

  • Canada

  • Latin America

  • By country

  • Brazil

  • Mexico

  • Argentina

  • Rest of Latin America

  • Europe

  • By country

  • UK

  • Germany

  • France

  • Spain

  • Italy

  • Russia

  • The rest of Europe

  • Asia Pacific

  • By country

  • China

  • Japan

  • India

  • Australia

  • South Korea

  • ASEAN

  • Rest of Asia-Pacific

  • Middle East

  • By country

  • GCC countries

  • Israel

  • Rest of the Middle East

  • Africa

  • By country

  • North Africa

  • central Africa

  • South Africa

Company Profiles

  • F.Hoffmann-La Roche Ltd.

  • Company presentation

  • Product portfolio

  • COMMERCIAL presence

  • Financial overview

  • Key developments

  • Strategies

  • BGI Group

  • Berry Genomics Co., Ltd.

  • Illumina, Inc.

  • Eurofin Scientific

  • Natera, Inc.

  • Sequenom, Inc.

  • Axia Women’s Health

  • Eluthia,

  • BillionToOne, Inc.

  • Incorporation of Quest Diagnostics.

  • Igenomix

  • Agilent Technologies, Inc.

  • Laboratory Corporation of America Holdings.

  • PerkinElmer, Inc.

  • Thermo Fisher Scientific

  • Yourgene Health PLC

Main topics covered:

1. Research objectives and hypotheses

2. Competence of the market

3. Market dynamics, regulation and trend analysis

4. Global Non-Invasive Prenatal Testing (NIPT) Market – Impact of Coronavirus (Covid-19) Pandemic

5. Global Non-Invasive Prenatal Testing (NIPT) Market, By Test Type, 2017-2030, (USD Million)

6. Global Non-Invasive Prenatal Testing (NIPT) Market, by Application, 2017-2030, (USD Million)

7. Global Non-Invasive Prenatal Testing (NIPT) Market, by End User, 2017-2030, (USD Million)

8. Global Non-Invasive Prenatal Testing (NIPT) Market, by Region, 2017-2030, (USD Million)

9. Competitive Landscape

10. Branch

For more information on this report, visit https://www.researchandmarkets.com/r/7nb76n

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900